Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GAIOLLA, RAFAEL
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	Active, not recruiting	3	650	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib	Loxo Oncology, Inc., Eli Lilly and Company	Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma	06/25	01/28
NCT02589548: Brazilian Prospective Hodgkin Lymphoma Registry	Recruiting	N/A	1400	RoW		Universidade Federal do Rio de Janeiro	Hodgkin Lymphoma, Hodgkin Disease	12/22	12/22
NCT05958134: Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL	Completed	N/A	600	RoW		AstraZeneca, Hospital Israelita Albert Einstein	Diffuse Large B Cell Lymphoma	06/24	06/24
MInamoto, Suzana Erico Tanni
BREATH, NCT05196581: Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources	Completed	2	100	RoW	Dispersible NaCl powder 10 sessions, Breathox, Dispersible NaCl powder 5 sessions	Suzana Erico Tanni Minamoto, Liita Care ApS	COVID-19	07/22	12/22
SASSAKI, LIGIA YUKIE
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26